Judith S. Kaur

Physiotherapy New Zealand — New Zealand

Medicine · Health Sciences

32h-index5.2kcitations167works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Global Cancer Incidence and Screening(53), Colorectal Cancer Screening and Detection(21), Virus-based gene therapy research(21), Palliative Care and End-of-Life Issues(20), Ethics in Clinical Research(13)

Publications167 total

Prevalence of musculoskeletal disorders and their impact on health-related quality of life among Punjabi bank employees: A cross-sectional study
Journal of Orthopaedic Reports·2025· 1 citedOpen Access
From Insufficient Data to New Models of Healthcare in the USA
2024Open Access
Provider- and System-Level Barriers and Facilitators to Colonoscopy and Multi-Target Stool DNA for Colorectal Cancer Screening in Rural/Remote Alaska Native Communities
International Journal of Environmental Research and Public Health·2023· 6 citedOpen Access
Strategies to increase accrual of underrepresented populations in Alliance NCTN trials.
Journal of Clinical Oncology·2023· 3 cited
Data from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Table 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Data from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 3 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 2 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 4 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure Legends 1-5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure Legends 1-5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Table 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 5 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 3 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 2 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 1 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
Supplementary Figure 4 from Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Svetomir N. Markovic(8), Edward T. Creagan(6), Linda Burhansstipanov(6), Jeff A. Sloan(5), Henry C. Pitot(5), Vera J. Suman(5), Mark Dignan(5), James N. Ingle(4), David K. Espey(4), Judith Swan(4), Charles L. Wiggins(4), Melissa A. Jim(4), Lisa A. Kottschade(4), Anne P. Lanier(4), Phyllis A. Wingo(3), Prema P. Peethambaram(3), Gary A. Croghan(3), Ronald L. Richardson(3), Robert R. McWilliams(3), Wendy K. Nevala(3)